These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

83 related items for PubMed ID: 2770701

  • 21. Increased expression of DNA topoisomerase I gene and collateral sensitivity to camptothecin in human cisplatin-resistant bladder cancer cells.
    Kotoh S, Naito S, Yokomizo A, Kumazawa J, Asakuno K, Kohno K, Kuwano M.
    Cancer Res; 1994 Jun 15; 54(12):3248-52. PubMed ID: 8205547
    [Abstract] [Full Text] [Related]

  • 22. Investigation of resistance to DNA cross-linking agents in 9L cell lines with different sensitivities to chloroethylnitrosoureas.
    Bodell WJ, Gerosa M, Aida T, Berger MS, Rosenblum ML.
    Cancer Res; 1985 Aug 15; 45(8):3460-4. PubMed ID: 3860285
    [Abstract] [Full Text] [Related]

  • 23. Radiation resistance in a melphalan-resistant subline of a rat mammary carcinoma.
    Lehnert S, Vestergaard J, Batist G, Aloui-Jamali MA.
    Radiat Res; 1994 Aug 15; 139(2):232-9. PubMed ID: 8052700
    [Abstract] [Full Text] [Related]

  • 24. Suppression of P-glycoprotein expression and multidrug resistance by DNA cross-linking agents.
    Ihnat MA, Lariviere JP, Warren AJ, La Ronde N, Blaxall JR, Pierre KM, Turpie BW, Hamilton JW.
    Clin Cancer Res; 1997 Aug 15; 3(8):1339-46. PubMed ID: 9815817
    [Abstract] [Full Text] [Related]

  • 25. Melphalan-induced DNA cross-linking in human melanoma cells and phytohaemagglutinin-stimulated lymphocytes in relation to intracellular drug content and cellular levels of glutathione.
    Hansson J, Edgren M, Ehrsson H, Lewensohn R, Ringborg U.
    Anticancer Res; 1987 Aug 15; 7(1):97-104. PubMed ID: 3566189
    [Abstract] [Full Text] [Related]

  • 26. Association between cisplatin resistance and mutation of p53 gene and reduced bax expression in ovarian carcinoma cell systems.
    Perego P, Giarola M, Righetti SC, Supino R, Caserini C, Delia D, Pierotti MA, Miyashita T, Reed JC, Zunino F.
    Cancer Res; 1996 Feb 01; 56(3):556-62. PubMed ID: 8564971
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Reduced levels of drug-induced DNA cross-linking in nitrogen mustard-resistant Chinese hamster ovary cells expressing elevated glutathione S-transferase activity.
    Robson CN, Lewis AD, Wolf CR, Hayes JD, Hall A, Proctor SJ, Harris AL, Hickson ID.
    Cancer Res; 1987 Nov 15; 47(22):6022-7. PubMed ID: 3664506
    [Abstract] [Full Text] [Related]

  • 29. Gene-specific formation and repair of DNA monoadducts and interstrand cross-links after therapeutic exposure to nitrogen mustards.
    Souliotis VL, Dimopoulos MA, Sfikakis PP.
    Clin Cancer Res; 2003 Oct 01; 9(12):4465-74. PubMed ID: 14555520
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Genotypic and phenotypic comparisons of de novo and acquired melphalan resistance in an isogenic multiple myeloma cell line model.
    Hazlehurst LA, Enkemann SA, Beam CA, Argilagos RF, Painter J, Shain KH, Saporta S, Boulware D, Moscinski L, Alsina M, Dalton WS.
    Cancer Res; 2003 Nov 15; 63(22):7900-6. PubMed ID: 14633719
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Alkylating agents: in vitro studies of cross-resistance patterns in human cell lines.
    Teicher BA, Cucchi CA, Lee JB, Flatow JL, Rosowsky A, Frei E.
    Cancer Res; 1986 Sep 15; 46(9):4379-83. PubMed ID: 3731096
    [Abstract] [Full Text] [Related]

  • 34. Xrcc3 induces cisplatin resistance by stimulation of Rad51-related recombinational repair, S-phase checkpoint activation, and reduced apoptosis.
    Xu ZY, Loignon M, Han FY, Panasci L, Aloyz R.
    J Pharmacol Exp Ther; 2005 Aug 15; 314(2):495-505. PubMed ID: 15843498
    [Abstract] [Full Text] [Related]

  • 35. Mechanisms of cross-resistance between radiation and antineoplastic drugs.
    Ozols RF, Masuda H, Hamilton TC.
    NCI Monogr; 1988 Aug 15; (6):159-65. PubMed ID: 3352759
    [Abstract] [Full Text] [Related]

  • 36. Topoisomerase II beta levels are a determinant of melphalan-induced DNA crosslinks and sensitivity to cell death.
    Emmons M, Boulware D, Sullivan DM, Hazlehurst LA.
    Biochem Pharmacol; 2006 Jun 28; 72(1):11-8. PubMed ID: 16678798
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. Transcriptional up-regulation of gamma-glutamylcysteine synthetase gene expression in melphalan-resistant human prostate carcinoma cells.
    Mulcahy RT, Untawale S, Gipp JJ.
    Mol Pharmacol; 1994 Nov 28; 46(5):909-14. PubMed ID: 7969079
    [Abstract] [Full Text] [Related]

  • 39. Characterization of a human small cell lung carcinoma cell line with acquired resistance to cis-diamminedichloroplatinum(II) in vitro.
    Hospers GA, Mulder NH, de Jong B, de Ley L, Uges DR, Fichtinger-Schepman AM, Scheper RJ, de Vries EG.
    Cancer Res; 1988 Dec 01; 48(23):6803-7. PubMed ID: 2846161
    [Abstract] [Full Text] [Related]

  • 40. Cellular resistance to chloroethylnitrosoureas, nitrogen mustard, and cis-diamminedichloroplatinum(II) in human glial-derived cell lines.
    Aida T, Bodell WJ.
    Cancer Res; 1987 Mar 01; 47(5):1361-6. PubMed ID: 3469016
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 5.